ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012
Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis.Advances in protein chemistry and structural biology · 2023Review
- The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.Cancer discovery · 2017Article
- The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox.The Journal of investigative dermatology · 2015Article
- The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells.The Journal of biological chemistry · 2015Article
- Pathways and therapeutic targets in melanoma.Oncotarget · 2014Review
- Combinatorial drug therapy for cancer in the post-genomic era.Nature biotechnology · 2012Review
- Genetics of melanoma.Frontiers in genetics · 2012Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The RAF inhibitor vemurafenib has unprecedented activity in BRAF-mutant melanomas, but resistance invariably develops. As Hsp90 is required for the stability of several of the oncoproteins that mediate RAF inhibitor resistance, inhibitors of this cellular chaperone may be effective in patients with intrinsic or acquired resistance to RAF inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.